Thymosin Beta-4 Sulfoxide (TB4-SO)
Also known as: Thymosin Beta-4 Sulfoxide, TB4-S, Oxidized TB4
Overview
Thymosin beta-4 sulfoxide (TB4-SO) is the naturally occurring oxidized form of Thymosin Beta-4 generated by methionine-6 oxidation. Unlike the reduced parent compound, TB4-SO does not bind G-actin and thus lacks TB-500's actin-sequestering activity. Instead, TB4-SO has potent and specific anti-inflammatory properties independent of G-actin binding—activating the Nrf2 transcription factor pathway to upregulate antioxidant and anti-inflammatory gene expression. TB4-SO is considered an important endogenous immunomodulatory signal in inflammatory conditions where ROS-mediated oxidation of TB4 occurs.
Mechanism of Action
TB4-SO specifically interacts with Kelch-like ECH-associated protein 1 (KEAP1), the E3 ubiquitin ligase that normally targets Nrf2 for proteasomal degradation. By binding KEAP1, TB4-SO displaces Nrf2 from the KEAP1-Nrf2 complex, allowing Nrf2 to translocate to the nucleus and activate antioxidant response elements (AREs). This drives expression of heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase-1 (NQO1), glutamate-cysteine ligase, and other cytoprotective enzymes. This mechanism is mechanistically distinct from TB4's G-actin binding and operates independently at sites of oxidative stress.
Potential Benefits
- Anti-inflammatory activity via Nrf2 pathway activation
- HO-1 upregulation with potent cytoprotective effects
- Antioxidant gene expression induction
- Endogenous anti-inflammatory signal generated under oxidative stress
- Potential in inflammatory bowel disease and oxidative stress conditions
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Research-only peptide |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | 4-12 weeks (research) |
Oxidized sulfoxide form of TB4 — proposed as the 'active' anti-inflammatory metabolite. Limited standalone human data.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Parallel to TB-500 administration.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Thymosin Beta-4 Sulfoxide (TB4-SO):
Extended Healing Stack
Research extension of the classic healing stack emphasizing the oxidized TB4 metabolite.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 2-5 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Ac-Ser-Asp-Lys-Pro-Asp-Met(O)-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser (Met6 → Met6-sulfoxide)
Side Effects & Safety
- Not independently characterized; see TB-500 entry
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Similar to TB-500 parent — ~2-3 hours plasma |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Thymosin Beta-4 Sulfoxide (TB4-SO) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.